who meeting jan 2013 · pdf filealain&townsend&...

24
Alain Townsend With Thanks to Ita Askonas Jane Sharpes Daniel Puleston Ervin Fodor Katja Simon Tim Powell And future thanks to Jon Silk Kanta Subbarao Lisa Smith Wendy Barclay Craig Waugh Kevin Clark

Upload: vutram

Post on 26-Mar-2018

229 views

Category:

Documents


5 download

TRANSCRIPT

Page 1: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Alain  Townsend  

With  Thanks  to  Ita  Askonas  

Jane  Sharpes      Daniel  Puleston  Ervin  Fodor      Katja  Simon  

Tim  Powell        And  future  thanks  to  Jon  Silk        Kanta  Subbarao  Lisa  Smith      Wendy  Barclay  

Craig  Waugh  Kevin  Clark  

Page 2: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Lancet July 8 1933

Page 3: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

ProperGes  Desired  of  a  Pre-­‐Pandemic    Live  AIenuated  Influenza  Vaccine  

1)  Can  infect  but  not  replicate  

2)  Is  Immunologically  complete  

3)  Cannot  donate  a  funcGonal  HaemaggluGnin  gene  to  Seasonal  Influenza  Viruses  

4)  Given  i.n.  to  promote  local  immune  responses  

5)  Induces  broad  immunity  at  least  within  an  HA  subtype  

Page 4: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

J Virol. 81, 9727, 2007.  

Page 5: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk
Page 6: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

ProducGon  of  Pseudotyped  Influenza  

MDCK  Cells  

No  Viable  Virus  

MDCK  +  PR8  HA  

PR8  HA  Pseudotype  ParGcles  

MDCK  +  Eng195  HA  

Eng195  HA  Pseudotype  ParGcles  

Page 7: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

S-­‐FLU  Nomenclature:  

[HA/NA  Genotype].Surface  HA  

[S-­‐eGFP/N1(PR8)].H1(PR8)  

[S-­‐eGFP/N1(Eng195)].H1(Eng195)  

[S-­‐eGFP/N1(PR8)].H5*(VN1203)  

Page 8: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk
Page 9: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk
Page 10: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk
Page 11: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Immune  Responses  to  S-­‐FLU  

Page 12: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Neutralising  AnGbody  Response  to    [S-­‐eGFP/N1(Eng195)].H1(Eng195)  v  [S-­‐eGFP/N1(PR8)].H1(PR8)  10x  Dose  (320  HAU)  i.p  

Page 13: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

[S-­‐eGFP/NA(PR8)].H1(PR8)  

S-­‐FLU  virus    is  not  pathogenic    

Cambridge  Strain  

Page 14: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Cross-­‐ProtecGon  by  S-­‐FLU  

Page 15: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Reduced  viral  replicaGon  on  challenge  

Page 16: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Normal  

S-­‐HA  /  X31  challenge  d3   S-­‐HA  /  PR8  Challenge  d3  

VGM  PR8  Challenge  Day  3  

Page 17: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Post  Challenge  Responses  

T  Cells   AnGbody  

Page 18: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Class  I  restricted  T  cells  from  the  LUNGS  Daniel  Puleston  

Young  

Control    Challenged  S-­‐Flu  Vaccine  +Challenged  

Old  

CD8+  

NP  366-­‐74/Db  Tetramer  

Page 19: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Importance  of  local  administraGon  -­‐  1  [S-­‐eGFP/NA(PR8)].H1(PR8)  Day  0  dose  1,  Day  14  dose  2,  Challenge  d  47.  In  32  HAU  Ip  320  HAU  

Page 20: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Intraperitoneal  priming  results  in  T  cells  in  the  spleen  but    less  in  the  lungs  

Local  Priming  

Page 21: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Heterotypic  Immunity  induced  by  [S-­‐eGFP/NA(Eng195)].H1(Eng195)  

A/PR/8/34    

Page 22: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Importance  of    local  administraGon  -­‐  2  

[S-­‐eGFP/NA(Eng195)].H1(Eng195)  Day  0  dose  1,  Day  14  dose  2,  Challenge  d  47.  In  32  HAU  Ip  320  HAU  

Page 23: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Summary:  

Non-­‐ReplicaGng  Pseudotyped  influenza  (S-­‐FLU)  can  provide  

Cross-­‐protecGve  immunity  to  Influenza  A  viruses  

Strong  local  T  cell  response  in  lung  

Moderate  strain  specific  anGbody  response  

Should  be  given  locally  to  lung  for  full  effect  

EffecGve  vaccine  dose  104  fold  less  than  recombinant  Adenovirus  

Page 24: WHO Meeting Jan 2013 · PDF fileAlain&Townsend& With&Thanks&to&Ita&Askonas& Jane&Sharpes & &&Daniel&Puleston& ErvinFodor & &&KatjaSimon TimPowell & &&And&future&thanks&to& JonSilk

Challenges:  

Aerosol  administraGon  

Generality  to  other  species  

Safety  

Yield  

Regulatory  issues